Stock Analysis of Sigilon Therapeutics Inc (SGTX)

Loading ...

Birds Eye View of Sigilon Therapeutics Inc

Birds's Eye

Technical Analysis of Sigilon Therapeutics Inc

Stock Analysis of Sigilon Therapeutics Inc (SGTX) - Birds Eye View

1W 2W 1M 3M 1Y 2Y 5Y

Overview

Code	SGTX
Close	22.47
Change	-0.590 / 2.56 %
Volume	81878.00
Vol Change	33782.00 / 70.24 %
Industry	Biotechnology
Sector	Healthcare

AIO Strength Index

Technical Strength	Mild Bullish
Growth Index	Poor Growth Stock
Value Index	Very Low Value Stock
Profitability Index	Poor Profitability Stock
Stability Index	Very Low Stability Stock

Fundamental View of Sigilon Therapeutics Inc

PE (TTM)

-480.75

Very Poor

Price / Book

372.28

Very Poor

Price / Sales

827.06

Very Poor

Piotroski F Score

2.0

Poor

Market Cap

56217.69 K

Enterprise Value

37324.69 K

All Financial Ratio's

ROA (TTM)

-36.03

Very Poor

ROE (TTM)

-77.44

Very Poor

Net Margin (TTM)

-172.03

Very Poor

Revenue

34.85 %

12944.00 K

Net Profit

43.65 %

-43561.00 K

Debt to Equity

0.592

Good

Altman Z Score

-4.28

Very Poor

Quick Ratio

2.39

Good

Cash Ratio

2.25

Good

Financial Statement Analysis

Highs/Lows of Sigilon Therapeutics Inc

Period	Old price	Stock Return	S&P 500 Returns	High	Low	High Date	Low Date
One Week	21.55	4.27 %	1.54 %	23.785	21.255	07-Aug-23	04-Aug-23
Two Week	21.35	5.25 %	3.42 %	23.785	20.61	07-Aug-23	28-Jul-23
One Month	21.87	2.74 %	5.60 %	23.785	20.61	07-Aug-23	28-Jul-23
Three Month	0.4921	4466.15 %	5.95 %	27.9999	0.45	29-Jun-23	17-May-23
Six Months	0.66	3304.55 %	17.48 %	27.9999	0.45	29-Jun-23	17-May-23
One year	0.739	2940.60 %	27.52 %	27.9999	0.29	29-Jun-23	27-Dec-22
Two year	5.47	310.79 %	29.70 %	27.9999	0.29	29-Jun-23	27-Dec-22

Technical View of Sigilon Therapeutics Inc

RSI

72.45

Mild Bearish

MACD

1.92

Bearish

ADX

67.67

Bullish

Super Trend

19.93

Mild Bullish

Williams %R

-41.42

Neutral

CCI

124.47

Bearish

Technical Analysis Deep Dive

EMA 5

22.53

Strong Bearish

EMA 15

21.67

Strong Bullish

EMA 50

16.15

Strong Bullish

EMA 100

11.04

Bullish

SMA 100

8.02

Bullish

SMA 200

4.31

Strong Bullish

SMA 5 / 20

22.63 / 21.62

Bullish

SMA 15 / 50

21.69 / 14.79

Bullish

SMA 50 / 200

14.79 / 4.31

Strong Bullish

MA Analysis Deep Dive

Charts of Sigilon Therapeutics Inc

Returns of Sigilon Therapeutics Inc with Peers

Period / Stock	SGTX	NSPR	DRIO	ENZ
1 Week	4.27%	2.91%	21.02%	4.81%
1 Mth	2.74%	4.07%	57.02%	-5.22%
3 Mth	4466.15%	-13.04%	-19.15%	-19.85%
6mth	3304.55%	-21.08%	59.66%	-16.15%
1 Year	2940.60%	30.68%	-48.92%	-52.81%
2 Year	310.79%	3.84%	-73.57%	-56.05%
5 Years	-	-95.31%	-87.46%	-70.05%
charts	-

View All Together in Chart Inline Tile

Compare Fundamentals of Sigilon Therapeutics Inc with Peers

Ratio / Stock	SGTX	NSPR	DRIO	ENZ
PE	-480.75	-16228.15	3.56	0.905
P/B	372.28	733.11	0.817	0.970
ROA	-36.03	-3.77	14.39	60.98
ROE	-77.44	-4.52	22.93	107.22
Debt To Equity	0.592	0.0141	0.493	0.0159
Revenue	12944.00 K 34.85 %	6205.00 K 20.00 %	23545.00 K 14.86 %	31061.00 K 70.99 %
Net Income	-43561.00 K 43.65 %	1292.00 K 106.99 %	-57758.00 K 190.48 %	-37321.00 K 104.38 %

Technicals of Sigilon Therapeutics Inc with Peers

Technical / Stock	SGTX	NSPR	DRIO	ENZ	-
ADX	67.67	17.57	13.65	32.85
CMF	-0.0460	0.0349	0.436	-0.0341
MFI	60.80	39.49	83.85	68.42
RSI	72.45	57.37	69.10	46.51
MACD Abv Signal	False	True	True	True
Price Above 50 MA	True	True	True	False	-
Price Above 200 MA	True	False	False	False	-

About : Sigilon Therapeutics Inc

Address : 100 Binney Street, Cambridge, MA, United States, 02142
Tel : 617 336 7540
URL : https://www.sigilon.com
Code : SGTX, ISIN : US82657L1070, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 04_Dec_2020
Employee Count : 62

Sigilon Therapeutics, Inc., a preclinical stage biotechnology company, develops functional cures for patients with acute and chronic diseases. Its lead product candidate is SIG-002 to replace islet cells for the treatment of type 1 diabetes; and SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-205, SIG-218, SIG-220, and SIG-005, which are to treat the non-neurological manifestations of mucopolysaccharidosis type 1; and SIG-207 is to treat of Fabry disease. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Note : All Data Generated at the End of Trading Hours (EOD Data)